Ferromagnetic crystals (magnetite?) in human tissue

In recent years, a variety of animals have been found which are able to synthesize the ferromagnetic mineral magnetite (Fe3O4). Lowenstam (1962) originally recognized biogenic magnetite in the radular teeth of a primitive marine mollusc, the chiton (Polyplacophora), and since then it has been identified as a precipitate in several magnetically sensitive organisms, including honey bees (Gould, Kirschvink & Deffeyes, 1978), homing pigeons (Walcott, Gould & Kirschvink, 1979) and in magnetotactic bacteria (Frankel, Blakemore & Wolfe, 1979). Zoeger, Dunn & Fuller (1980) also report a localized concentration of magnetite in dolphin heads, although magnetosensory behavioural experiments have not as yet been done on them. Magnetite is biologically unique because it is both ferromagnetic and conducts electricity like a metal; consequently it interacts strongly with magnetic and electric fields. Due to the numerous industrial and research environments which expose people to artificially intense electromagnetic conditions, it is of importance to know whether or not this material might exist in human tissue. Kirschvink & Gould (1980) have argued that there are probably one or more non-sensory metabolic functions for magnetite from which specialized magnetoreceptors could have evolved; consequently one might expect to find small amounts of magnetite in all animals, including humans. In an attempt to partially answer this question, I searched for magnetic remanence in four intact human adrenal glands which had been removed during autopsy and were frozen quickly in non-magnetic containers. Results of this analysis are shown on Fig. 1. Indeed, there is a measurable amount of high-coercivity ferromagnetic material present which appears to be finely disseminated throughout the tissue. Between 1 and 10 million single-domain magnetite crystals per gram would be necessary to account for the observed magnetic remanence. Although these measurements do not uniquely identify the crystal phase as magnetite, no other ferromagnetic minerals have ever been observed as biologic precipitates. Positive identification, of course, awaits the development of magnetic separation techniques capable of isolating and purifying these submicroscopic crystals. Barnothy & Sümegi (1969) have shown that mouse adrenals are particularly prone to degeneration in moderately strong magnetic fields; this effect might be due to the presence of magnetite

Detection of secretory IgA antibodies against gliadin and human tissue transglutaminase in stool to screen for coeliac disease in children: validation study

Objective To evaluate two commercial stool tests for detection of secretory IgA antibodies against gliadin and human tissue transglutaminase for diagnosis of coeliac disease in children with symptoms.Setting Tertiary care children's hospital.Participants Coded stool samples from 20 children with newly diagnosed coeliac disease and 64 controls. Six children with coeliac disease had stool tests every two weeks for three months after starting a gluten-free diet.Main outcome measures Secretory IgA antibodies against gliadin and human tissue transglutaminase in stool samples, determined in duplicate by using recommended cut-off limits.Results Sensitivity of faecal antibodies against human tissue transglutaminase was 10% (95% confidence interval 1% to 32%), and specificity was 98% (91% to 100%). For antibodies against gliadin, sensitivity was 6% (0% to 29%) and specificity was 97% (89% to 100%). Optimisation of cut-off limits by receiver operating characteristic analysis and use of results of both tests increased sensitivity to 82%, but specificity decreased to 58%. All follow-up stool tests remained negative, except for two positive anti-gliadin results in one patient, six and 10 weeks after the gluten-free diet was started.Conclusions Neither stool test was suitable for screening for coeliac disease in children with symptoms

Human Tissue Oversight

Information on the oversight structures in place for the dealing with of human tissue in HSC activities. This includes mention of the Human Tissue Oversight Committee (HTOC) and the UNM HSC Human Tissue Repository (HTR)

Intestinal fungi contribute to development of alcoholic liver disease

This study was supported in part by NIH grants R01 AA020703, U01 AA021856 and by Award Number I01BX002213 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (to B.S.). K.H. was supported by a DFG (Deutsche Forschungsgemeinschaft) fellowship (HO/ 5690/1-1). S.B. was supported by a grant from the Swiss National Science Foundation (P2SKP3_158649). G.G. received funding from the Yale Liver Center NIH P30 DK34989 and R.B. from NIAAA grant U01 AA021908. A.K. received support from NIH grants RC2 AA019405, R01 AA020216 and R01 AA023417. G.D.B. is supported by funds from the Wellcome Trust. We acknowledge the Human Tissue and Cell Research (HTCR) Foundation for making human tissue available for research and Hepacult GmbH (Munich, Germany) for providing primary human hepatocytes for in vitro analyses. We thank Dr. Chien-Yu Lin Department of Medicine, Fu-Jen Catholic University, Taiwan for statistical analysis.Peer reviewedPublisher PD

A Brief Comparison Between Available Bio-printing Methods

The scarcity of organs for transplant has led to large waiting lists of very sick patients. In drug development, the time required for human trials greatly increases the time to market. Drug companies are searching for alternative environments where the in-vivo conditions can be closely replicated. Both these problems could be addressed by manufacturing artificial human tissue. Recently, researchers in tissue engineering have developed tissue generation methods based on 3-D printing to fabricate artificial human tissue. Broadly, these methods could be classified as laser-assisted and laser free. The former have very fine spatial resolutions (10s of $\mu$m) but suffer from slow speed ( $< 10^2$ drops per second). The later have lower spatial resolutions (100s of $\mu$ m) but are very fast (up to $5\times 10^3$ drops per second). In this paper we review state-of-the-art methods in each of these classes and provide a comparison based on reported resolution, printing speed, cell density and cell viability

Time-of-flight resolved light field fluctuations reveal deep human tissue physiology.

Red blood cells (RBCs) transport oxygen to tissues and remove carbon dioxide. Diffuse optical flowmetry (DOF) assesses deep tissue RBC dynamics by measuring coherent fluctuations of multiply scattered near-infrared light intensity. While classical DOF measurements empirically correlate with blood flow, they remain far-removed from light scattering physics and difficult to interpret in layered media. To advance DOF measurements closer to the physics, here we introduce an interferometric technique, surmounting challenges of bulk motion to apply it in awake humans. We reveal two measurement dimensions: optical phase, and time-of-flight (TOF), the latter with 22 picosecond resolution. With this multidimensional data, we directly confirm the unordered, or Brownian, nature of optically probed RBC dynamics typically assumed in classical DOF. We illustrate how incorrect absorption assumptions, anisotropic RBC scattering, and layered tissues may confound classical DOF. By comparison, our direct method enables accurate and comprehensive assessment of blood flow dynamics in humans

Human Tissue Plasminogen Activator

Tissue plasminogen activator (tPA) has long been considered the flagship product of the biotechnology industry. This protein is a popular treatment for heart attacks, coronary heart disease, and stroke. Genentech has held a patent for the development of tPA-producing cells and sold it for approximately $2,000 per 100-mg dose. Within the next few years this patent will expire and the opportunity will exist to produce a generic form of tPA at a fraction of the cost. This design report describes a plant that can manufacture this recombinant protein without spending$500 MM on research and development costs. A cheap, generic form of tPA can acquire a large share of the current $300 MM tPA market. The FDA has recently prohibited the sale Abbott Laboratories\u27 thrombolytic drug, urokinase. The only other thrombolytic medication available is streptokinase (SK); while it is much cheaper, SK causes more severe side effects and is somewhat less effective than tPA. It is therefore likely that the market for a generic tPA will expand as the price decreases. For this reason we have designed our plant to produce approximately 80 kg per year. Plant calculations were completed by hand and with the use of the SuperPro Designer program (for the Separation Section). Costing was completed using the economic spreadsheet created by Holger Nickisch. Purchase costs were obtained as company quotes or estimates from the design consultants. Our pharmaceutical plant has an investor\u27s rate of return of 59.7$104 MM. Given the profitability of this process we highly recommend construction of this plant